Details for New Drug Application (NDA): 205596
✉ Email this page to a colleague
The generic ingredient in NOXAFIL is posaconazole. There are twenty-one drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the posaconazole profile page.
Summary for 205596
Tradename: | NOXAFIL |
Applicant: | Merck Sharp Dohme |
Ingredient: | posaconazole |
Patents: | 6 |
Suppliers and Packaging for NDA: 205596
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
NOXAFIL | posaconazole | SOLUTION;INTRAVENOUS | 205596 | NDA | Merck Sharp & Dohme LLC | 0085-4331 | 0085-4331-01 | 1 VIAL, GLASS in 1 CARTON (0085-4331-01) / 16.7 mL in 1 VIAL, GLASS |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 300MG/16.7ML (18MG/ML) | ||||
Approval Date: | Mar 13, 2014 | TE: | AP | RLD: | Yes | ||||
Regulatory Exclusivity Expiration: | Jun 17, 2028 | ||||||||
Regulatory Exclusivity Use: | FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IN ADULTS AND PEDIATRIC PATIENTS 13 YEARS OF AGE AND OLDER | ||||||||
Regulatory Exclusivity Expiration: | Jun 17, 2024 | ||||||||
Regulatory Exclusivity Use: | FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IN PATIENTS 13 YEARS OF AGE AND OLDER | ||||||||
Regulatory Exclusivity Expiration: | May 31, 2024 | ||||||||
Regulatory Exclusivity Use: | NEW PATIENT POPULATION |
Expired US Patents for NDA 205596
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Merck Sharp Dohme | NOXAFIL | posaconazole | SOLUTION;INTRAVENOUS | 205596-001 | Mar 13, 2014 | ⤷ Sign Up | ⤷ Sign Up |
Merck Sharp Dohme | NOXAFIL | posaconazole | SOLUTION;INTRAVENOUS | 205596-001 | Mar 13, 2014 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription